Article
Medicine, General & Internal
Luming Zheng, Ling Li, Qingqing He, Meng Wang, Yunhan Ma, Jian Zhu, Yanchen Li, Xiaokang Fu, Yaxuan Zhang
Summary: ATC is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options. This case suggests that immunotherapy based on PD-L1 evaluation provides a therapeutic option for ATC patients, and targeting programmed cell death protein 1/PD-L1 may provide a much-needed treatment option for patients with advanced ATC.
Article
Oncology
Yurou Xing, Yongsheng Wang, Xin Wu
Summary: This article presents a case of multiple postoperative recurrences of papillary thyroid carcinoma that eventually transformed into undifferentiated carcinoma. The patient had a huge neck mass that was unsuitable for surgery. However, remarkable tumor shrinkage was achieved through tislelizumab immunotherapy combined with radiotherapy. Further research is needed to study the efficacy of this combination treatment.
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
Zhen Xu, Hyo Shik Shin, Yoo Hyung Kim, Seong Yun Ha, Jae-Kyung Won, Su-jin Kim, Young Joo Park, Sareh Parangi, Sun Wook Cho, Kyu Eun Lee
Summary: This study aimed to establish a novel orthotopic ATC model in C57BL/6 mice and characterize the tumor microenvironment focusing immunity in the model. The results showed that compared with the B6129SF1 mouse model, this new model exhibited more aggressive tumor cell behaviors and strong immune responses.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Shyang-Rong Shih, Kuan-Hua Chen, Kuan-Yu Lin, Pan-Chyr Yang, Kuen-Yuan Chen, Chun-Wei Wang, Chun-Nan Chen, Chih-Feng Lin, Chia-Chi Lin
Summary: This study analyzed four cases of immunotherapy for unresectable anaplastic thyroid cancer (ATC). The results showed significant variability in treatment responses, highlighting the need for careful monitoring of both treatment efficacy and side effects in ATC patients.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2022)
Article
Immunology
Lin Gui, Yiming Zhu, Xiaomo Li, Xiaohui He, Tonghui Ma, Yi Cai, Shaoyan Liu
Summary: In this study, we present a case of an ATC patient with concurrent NRAS/BRAF non-V600 mutations who achieved a complete pathological response with a combination of immunotherapy and targeted therapy. This is the first report of successful treatment using this combination for ATC patients with NRAS/BRAF non-V600 mutations, indicating the need for further investigation into the mechanism of overcoming initial immunotherapy resistance mediated by these mutations.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Endocrinology & Metabolism
Nancy Y. Lee, Nadeem Riaz, Vanessa Wu, Thomas Brinkman, Chiaojung J. Tsai, Wanquing Zhi, James Fetten, Alan Ho, Richard J. Wong, Ronald Ghossein, Michael Tuttle, James Fagin, David G. Pfister, Eric Sherman
Summary: This pilot study evaluated the effectiveness of tremelimumab plus durvalumab with stereotactic body radiotherapy (SBRT) in improving overall survival (OS) in patients with metastatic anaplastic thyroid cancer (ATC). The results showed that this combination therapy did not improve OS in ATC patients. Further research is needed to explore novel immunotherapy combinations with or without radiotherapy for the treatment of ATC.
Article
Oncology
Rozita Bagheri-Yarmand, Naifa L. Busaidy, Elena McBeath, Brian P. Danysh, Kurt W. Evans, Tyler J. Moss, Argun Akcakanat, Patrick K. S. Ng, Christina M. Knippler, Jalyn A. Golden, Michelle D. Williams, Asha S. Multani, Maria E. Cabanillas, Kenna R. Shaw, Funda Meric-Bernstam, Manisha H. Shah, Matthew D. Ringel, Marie Claude Hofmann
Summary: This study identified a novel RAC1 (P34R) mutation acquired during dabrafenib treatment, as well as revealed that an increase in RAC1 copy numbers and polyploidy of chromosome 7 may contribute to drug resistance.
Article
Biology
Luz Maria Palacios, Victoria Peyret, Maria Estefania Viano, Romina Celeste Geysels, Yair Aron Chocobar, Ximena Volpini, Claudia Gabriela Pellizas, Juan Pablo Nicola, Claudia Cristina Motran, Maria Cecilia Rodriguez-Galan, Laura Fozzatti
Summary: This article introduces a new approach for treating anaplastic thyroid cancer (ATC) by targeting immune checkpoints in tumor-associated macrophages, aiming to improve the prognosis of patients.
Article
Biotechnology & Applied Microbiology
Chao Feng, Yujia Tao, Chao Yu, Lirui Wang, Xiao Liu, Yuan Cao
Summary: The tumor immune microenvironment (TIME) in anaplastic thyroid carcinoma (ATC) is a complex and diverse ecosystem. This study reveals the dynamic changes of TIME in both papillary thyroid carcinoma (PTC) and ATC at the single-cell level. The findings demonstrate the presence of immunosuppressive factors and decreased immune cell infiltration in ATC, providing insights for targeted therapy to activate the anti-tumor immune response.
CANCER GENE THERAPY
(2023)
Article
Endocrinology & Metabolism
Keith C. Bible, Electron Kebebew, James Brierley, Juan P. Brito, Maria E. Cabanillas, Thomas J. Clark, Antonio Di Cristofano, Robert Foote, Thomas Giordano, Jan Kasperbauer, Kate Newbold, Yuri E. Nikiforov, Gregory Randolph, M. Sara Rosenthal, Anna M. Sawka, Manisha Shah, Ashok Shaha, Robert Smallridge, Carol K. Wong-Clark
Summary: The guidelines for the management of anaplastic thyroid cancer (ATC) aim to provide evidence-based recommendations to inform clinical decision-making, encompassing diagnosis, treatment goals, locoregional and advanced disease approaches, palliative care, surveillance, and ethical considerations.
Article
Oncology
Jin-Seok Lee, Jun Sung Lee, Hyeok Jun Yun, Hojin Chang, Seok Mo Kim, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park
Summary: This study aimed to exhibit the clinical characteristics of anaplastic thyroid cancer (ATC) with distant metastasis, which is associated with a high mortality risk. Brain MRI or CT should be considered at diagnosis and follow-up, even in patients without neurological symptoms.
Article
Oncology
Meng Li, Qiyuan Bao, Zhusheng Zhang, Beichen Wang, Zhuochao Liu, Junxiang Wen, Rong Wan, Yuhui Shen, Weibin Zhang
Summary: This case report reveals that tumor site infection may enhance the efficacy of immune checkpoint inhibitors in the treatment of osteosarcoma, as demonstrated by a 14-year-old boy with pulmonary metastatic osteosarcoma who experienced rapid remission after treatment with a PD-1 inhibitor. Correlative analysis showed increased CD8+ T cell infiltration, PD-L1 expression, IFN-gamma expression, and upregulation of checkpoint targets after infection.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Maxwell J. Kroloff, Josefin-Beate Holz, Omer Stern, Christopher J. Shepherd, Michelle Morrow, Louis Kayitalire, Deborah J. Wong
Summary: This article presents a case of a patient with BRAF V600E-mutated, PD-L1 positive anaplastic thyroid cancer refractory to standard therapies, but achieving 3 years of disease control and partial response through treatment with FS118. Further investigation is needed to understand the mechanism of dual PD-L1/LAG-3 blockade by FS118 in overcoming initial PD-1 pathway resistance.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Endocrinology & Metabolism
Lingyun Zhang, Zhixiang Ren, Zhengzheng Su, Yang Liu, Tian Yang, Minyuan Cao, Yong Jiang, Ying Tang, Haining Chen, Weihan Zhang, Rixiang Gong, Tao Wei, Yong Peng, Bo Liu, Wei Zhang, Li Yang, Yiguo Hu, Zhihui Li, Jingqiang Zhu, Heng Xu, Yang Shu, Han Luo
Summary: A study conducted in West China Hospital revealed shared and ethnicity-specific genomic profiles of anaplastic thyroid cancer (ATC) in Chinese patients, suggesting that NOTCH2NL may act as a novel candidate driver gene for ATC tumorigenesis.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Pia Adam, Stefan Kircher, Iuliu Sbiera, Viktoria Florentine Koehler, Elke Berg, Thomas Knoesel, Benjamin Sandner, Wiebke Kristin Fenske, Hendrik Blaeker, Constantin Smaxwil, Andreas Zielke, Bence Sipos, Stephanie Allelein, Matthias Schott, Christine Dierks, Christine Spitzweg, Martin Fassnacht, Matthias Kroiss
Summary: High tumoral expression of PD-L1 in a large proportion of ATCs and a subgroup of PDTCs provides a rationale for immune checkpoint inhibition. FGFR expression is generally low in thyroid tumor cells. No impact of PD-L1 and FGFR 1-4 expression was observed on disease specific survival. The clinically observed synergism of PEM with LEN may be caused by immune modulation.
FRONTIERS IN ENDOCRINOLOGY
(2021)